Jun 26 |
Is Precigen (NASDAQ:PGEN) In A Good Position To Invest In Growth?
|
Jun 4 |
Precigen (NASDAQ:PGEN) shareholders are up 15% this past week, but still in the red over the last three years
|
Jun 3 |
Precigen stock rallies 17% on data for PRGN-2012 gene therapy
|
Jun 3 |
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
|
Jun 1 |
Investors Prep For A Key Jobs Report
|
May 23 |
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
|
May 14 |
Precigen GAAP EPS of -$0.10 misses by $0.01, revenue of $1.07M misses by $0.41M
|
May 14 |
Precigen Reports First Quarter 2024 Financial Results and Business Updates
|
May 13 |
Precigen Q1 2024 Earnings Preview
|
May 8 |
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
|